Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy

HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the...

Full description

Saved in:
Bibliographic Details
Published in:Proc Natl Acad Sci U S A
Main Authors: Floros, Konstantinos V., Lochmann, Timothy L., Hu, Bin, Monterrubio, Carles, Hughes, Mark T., Wells, Jason D., Morales, Cristina Bernadó, Ghotra, Maninderjit S., Costa, Carlotta, Souers, Andrew J., Boikos, Sosipatros A., Leverson, Joel D., Tan, Ming, Serra, Violeta, Koblinski, Jennifer E., Arribas, Joaquin, Prat, Aleix, Paré, Laia, Miller, Todd W., Dozmorov, Mikhail G., Harada, Hisashi, Windle, Brad E., Scaltriti, Maurizio, Faber, Anthony C.
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2018
Subjects:
PNAS Plus
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856537/
https://ncbi.nlm.nih.gov/pubmed/29476008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1717820115
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items